Patents by Inventor Bradley L. Smith

Bradley L. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
    Publication number: 20190219581
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 18, 2019
    Applicants: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
    Publication number: 20180031559
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Applicants: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
    Publication number: 20160091493
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: December 10, 2015
    Publication date: March 31, 2016
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Method for predicting the response to HER2-directed therapy
    Patent number: 9239331
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: January 19, 2016
    Assignees: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
    Publication number: 20150125448
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: January 13, 2015
    Publication date: May 7, 2015
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Method for predicting the response to HER2-directed therapy
    Patent number: 8956822
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: February 17, 2015
    Assignees: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
    Publication number: 20130302829
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: July 18, 2013
    Publication date: November 14, 2013
    Applicants: Cell Signaling Technology, Inc., Ventana Medical Systems, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Method for predicting the response to HER2-directed therapy
    Patent number: 8512967
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: August 20, 2013
    Assignees: Ventana Medical Systems, Inc., Cell Signaling Technology, Inc.
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
    Publication number: 20110136149
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: February 11, 2011
    Publication date: June 9, 2011
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
    Patent number: 7105642
    Abstract: The invention provides monoclonal antibodies that bind the estrogen receptor ? (ER ?) when phosphorylated at serine 118 (Ser118) in the N-terminal domain, but do not bind to ER ? when not phosphorylated at this site. Also provided are methods for determining the phosphorylation of ER ? in a biological sample, profiling ER ? activation in a test tissue, and identifying a compound that modulates phosphorylation of ER ? in a test tissue, by using the disclosed monoclonal antibodies. The sample or test tissue may be taken from a subject suspected of having cancer, such as breast cancer. Kits comprising the phospho-ER ? (Ser118) monoclonal antibodies of the invention are also provided.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: September 12, 2006
    Assignee: Cell Signalling Technology, Inc.
    Inventors: Bradley L. Smith, Katherine Crosby, Jiong Wu
  • Method for predicting the response to HER2-directed therapy
    Publication number: 20040248151
    Abstract: This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.
    Type: Application
    Filed: December 11, 2003
    Publication date: December 9, 2004
    Applicants: Ventana Medical Systems, Inc., Cell Signaling Technology
    Inventors: Sarah S. Bacus, Bradley L. Smith
  • Methods and materials for examining pathways associated with glioblastoma progression
    Publication number: 20040106141
    Abstract: The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregulated in pathologies such as cancer and to reagents and kits adapted for performing such methods.
    Type: Application
    Filed: November 5, 2003
    Publication date: June 3, 2004
    Applicant: The Regents of the University of California
    Inventors: Paul S. Mischel, Charles L. Sawyers, Bradley L. Smith, Katherine Crosby
  • Methods for detecting BCR-ABL signaling activity in tissues using phospho-specific antibodies
    Publication number: 20030190688
    Abstract: The invention provides novel reagents and methods for detecting BCR-ABL or c-Abl kinase activity, and/or Abl signaling pathway activation in a cell or tissue, and discloses novel biomarkers relevant to Abl-mediated disease progression and therapeutic responsiveness, and provides predictive and detection methods based on the same. Phosphorylated BCR-ABL (Tyr245) and/or c-Abl (Tyr245), BCR-ABL (Tyr735) and/or c-Abl (Tyr735), Bcr (Tyr177), CRKL (Tyr207), Gab1 (Tyr627), PYK2 (Tyr402), Tyk2 (Tyr1054/1055), SHP2 (Tyr580), ERK1/2 (Thr202/Tyr204) and MEK1/2 (Ser217/221) have now been identified as relevant biomarkers of c-Abl pathway-mediated disease, and phospho-specific antibodies to these targets are provided. Kits for carrying out the methods of the invention are also provided.
    Type: Application
    Filed: April 7, 2003
    Publication date: October 9, 2003
    Applicant: Cell Signaling Technology, Inc.
    Inventors: Katherine Crosby, Bradley L. Smith, Valerie L. Goss
  • Molecular profiling of disease and therapeutic response using phospho-specific antibodies
    Publication number: 20030190689
    Abstract: The present invention provides methods for identifying the most relevant signal transduction pathway biomarkers of disease progression, outcome, or therapeutic responsiveness, using phospho-specific antibodies in cellular assays to identify proteins whose activity is correlated to the relevant outcome (e.g. therapeutic responsiveness). The invention also provides a method for utilizing correlated biomarker(s) to predict patient response to a therapeutic composition having efficacy against a disease involving altered signal transduction by employing one or more phospho-specific antibodies to detect activation status of such biomarker(s) in cellular assays. Kits for carrying out the methods of the invention are also provided.
    Type: Application
    Filed: April 7, 2003
    Publication date: October 9, 2003
    Applicant: CELL SIGNALING TECHNOLOGY,INC.
    Inventors: Katherine Crosby, Bradley L. Smith
  • Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
    Publication number: 20030099641
    Abstract: The invention provides monoclonal antibodies that bind the estrogen receptor &agr; (ER &agr;) when phosphorylated at serine 118 (Ser118) in the N-terminal domain, but do not bind to ER &agr; when not phosphorylated at this site. Also provided are methods for determining the phosphorylation of ER &agr; in a biological sample, profiling ER &agr; activation in a test tissue, and identifying a compound that modulates phosphorylation of ER &agr; in a test tissue, by using the disclosed monoclonal antibodies. The sample or test tissue may be taken from a subject suspected of having cancer, such as breast cancer. Kits comprising the phospho-ER &agr; (Ser118) monoclonal antibodies of the invention are also provided.
    Type: Application
    Filed: August 2, 2002
    Publication date: May 29, 2003
    Applicant: CELL SIGNALING TECHNOLOGY, INC.
    Inventors: Bradley L. Smith, Katherine Crosby, Jiong Wu